{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004810","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.642408+00:00","generated_at":"2026-05-17T23:26:32.982028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints","bullets":["Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%","Regenerative Solutions revenue rose 41% driven by Integrity implant outperformance (full-year 2024 surpassed in H1 2025)","Hyalofast Phase III trial missed co-primary endpoints but showed statistically significant improvements in secondary endpoints; final PMA module on track for H2 2025","Company reaffirms 2025 revenue/EBITDA guidance but revises long-term outlook for Hyalofast launch potential delay to 2027","Operating expenses down 17% YoY; production yield issues resolved in June 2025 with no patient impact"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004810","json":"https://secwatch.observer/filing/0001171843-25-004810.json","markdown":"https://secwatch.observer/filing/0001171843-25-004810.md","text":"https://secwatch.observer/filing/0001171843-25-004810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/0001171843-25-004810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/f8k_073025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T23:26:32.982028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}